Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003668.pdf
0001047469-15-003668.rtf
0001047469-15-003668.xls
8-A12B

Registration of certain classes of securities 12(b) of the Securities Exchange Act

 View HTML
0001104659-15-030565.pdf
0001104659-15-030565.rtf
0001104659-15-030565.xls
CORRESP

CORRESP

 View HTML
0001104659-15-030559.pdf
0001104659-15-030559.rtf
0001104659-15-030559.xls
CORRESP

CORRESP

 View HTML
0001104659-15-030564.pdf
0001104659-15-030564.rtf
0001104659-15-030564.xls
CERTNAS

CERTNAS

 View HTML
9999999997-15-008888.pdf
9999999997-15-008888.rtf
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

 View HTML
0001104659-15-031752.pdf
0001104659-15-031752.rtf
0001104659-15-031752.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001012975-15-000312.pdf
0001012975-15-000312.rtf
0001012975-15-000312.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0000315066-15-002587.pdf
0000315066-15-002587.rtf
0000315066-15-002587.xls
EFFECT

EFFECT

 View HTML
9999999995-15-001054.pdf
9999999995-15-001054.rtf
9999999995-15-001054.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031949.pdf
0001104659-15-031949.rtf
0001104659-15-031949.xls